Evidence map›Paper›PMID 39969959›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2025

Spatial Transcriptomics of Intraductal Papillary Mucinous Neoplasms Reveals Divergent Indolent and Malignant States.

Matthew K Iyer, Ashley A Fletcher, Jude Ogechukwu Okoye, Chanjuan Shi, Fengming Chen, Elishama N Kanu, Austin M Eckhoff, Matthew Bao, Marina Pasca di Magliano, Timothy L Frankel and 3 more

Abstract read
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Matthew K IyerDepartment of Surgery, Duke University, Durham, North Carolina.ORCID 0000-0002-0217-7390
Ashley A FletcherDepartment of Surgery, Duke University, Durham, North Carolina.ORCID 0000-0003-2626-4867
Jude Ogechukwu OkoyeDepartment of Surgery, University of Michigan, Ann Arbor, Michigan.ORCID 0000-0002-7194-5592
Chanjuan ShiDepartment of Pathology, Duke University, Durham, North Carolina.ORCID 0000-0001-5962-6479
Fengming ChenDepartment of Pathology, Duke University, Durham, North Carolina.ORCID 0000-0002-6406-0948
Elishama N KanuDepartment of Surgery, Duke University, Durham, North Carolina.ORCID 0000-0003-4959-9993
Austin M EckhoffDepartment of Surgery, Duke University, Durham, North Carolina.ORCID 0000-0002-6058-4971
Matthew BaoDepartment of Surgery, Duke University, Durham, North Carolina.ORCID 0009-0001-3903-8319
Marina Pasca di MaglianoDepartment of Surgery, University of Michigan, Ann Arbor, Michigan.ORCID 0000-0001-9632-9035
Timothy L FrankelDepartment of Surgery, University of Michigan, Ann Arbor, Michigan.ORCID 0000-0001-5987-0404
Arul M ChinnaiyanMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, Michigan.ORCID 0000-0001-9282-3415
Daniel P NussbaumDepartment of Surgery, Duke University, Durham, North Carolina.ORCID 0000-0003-3070-6605
Peter J AllenDepartment of Surgery, Duke University, Durham, North Carolina.ORCID 0000-0001-7912-9197

Funding

XenograftP30CA046592 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Eric R. Fearon · 1988 to 2026
$178.2M
Women's Cancer Research ProgramP30CA014236 · NCI · DUKE UNIVERSITY · PI Laura Fish · 1985 to 2026
$174.8M
Tumor Microenvironment Crosstalk Drives Early Lesions in Pancreatic CancerU54CA274371 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Elana Fertig · 2022 to 2026
$9.5M
Biomarker validation for intraductal papillary mucinous neoplasms of the pancreasR01CA182076 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Peter J Allen · 2014 to 2026
$3.6M
Targeting the fibroblast-immune cell crosstalk to relieve immune suppression in the pancreatic cancer microenvironmentR01CA260752 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI PASCA DI MAGLIANO, MARINA · 2022 to 2025
$2.8M
Dissecting the role of Notch signaling in the pancreatic cancer microenvironment.R01CA271510 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Filip Bednar, Marina Pasca Di Magliano · 2022 to 2026
$2.6M
Interrupting Cellular Crosstalk in the Immunosuppressive Microenvironment of Pancreas CancerU01CA224145 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CRAWFORD, HOWARD C., PASCA DI MAGLIANO, MARINA · 2017 to 2021
$2.6M
Mechanisms of myeloid cell driven pancreatic plasticity and carcinogenesisR01CA268426 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Timothy Louis Frankel, Marina Pasca Di Magliano · 2023 to 2026
$2.5M
Investigating GLI transcription factors as regulators of the pancreatic cancer microenvironmentR01CA275182 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Benjamin Allen, Marina Pasca Di Magliano · 2023 to 2026
$2.4M
Epithelial-immune cell crosstalk during injury and recovery in acute pancreatitisR01DK128102 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Timothy Louis Frankel · 2022 to 2026
$2.2M
BLRD VA I01 BX005777Michigan Department of Military and Veterans Affairs (DMVA) 5I01BX005777National Cancer Institute (NCI) 3P30CA014236-49S2National Cancer Institute (NCI) 3P30CA046592-34S1National Institutes of Health (NIH) 2T32Al141342-06National Institutes of Health (NIH) 5R01CA182076-07National Institutes of Health (NIH) 5R01DK128102National Institutes of Health (NIH) R01CA260752National Institutes of Health (NIH) R01CA268426National Institutes of Health (NIH) U54CA274371NCI NIH HHS P30 CA014236NCI NIH HHS P30 CA046592NCI NIH HHS R01 CA182076NCI NIH HHS R01 CA260752NCI NIH HHS R01 CA268426NCI NIH HHS R01 CA271510NCI NIH HHS R01 CA275182NCI NIH HHS U01 CA224145NCI NIH HHS U54 CA274371NIDDK NIH HHS R01 DK128102
6 · The paper itself

Abstract

purposeIntraductal papillary mucinous neoplasms (IPMN) occur in 5% to 10% of the population, but only a small minority progress to pancreatic ductal adenocarcinoma (PDAC). The lack of accurate predictors of high-risk disease leads to both unnecessary operations for indolent neoplasms and missed diagnoses of PDAC. Digital spatial RNA profiling (DSP-RNA) provides an opportunity to define and associate transcriptomic states with cancer risk. EXPERIMENTAL

designWe performed whole-transcriptome DSP-RNA profiling on 10 IPMN specimens encompassing the spectrum of dysplastic changes from normal duct to cancer. Epithelial regions within each tissue were annotated as normal duct, low-grade dysplasia, high-grade dysplasia, or invasive carcinoma. The resulting digital gene expression data were analyzed with R/Bioconductor.

resultsOur analysis uncovered three distinct epithelial transcriptomic states-"normal-like" (cNL), "low risk" (cLR), and "high risk" (cHR)-which were significantly associated with pathologic grade. Furthermore, the three states were significantly correlated with the exocrine, classical, and basal-like molecular subtypes described in PDAC. Specifically, exocrine function diminished in cHR, classical activation distinguished neoplasia (cLR and cHR) from cNL, and basal-like genes were specifically upregulated in cHR. Intriguingly, markers of cHR were detected in normal duct and low-grade dysplasia regions from specimens with PDAC but not from specimens containing only low-grade IPMN.

conclusionsDSP-RNA of IPMN revealed low-risk (indolent) and high-risk (malignant) expression programs that correlated with the activity of exocrine and basal-like PDAC signatures, respectively, and distinguished pathologically low-grade specimens from malignant specimens. These findings contextualize IPMN pathogenesis and have the potential to improve risk stratification.

Indexed as

Adenocarcinoma, MucinousBiomarkers, TumorCarcinoma, Pancreatic DuctalCarcinoma, PapillaryPancreatic Intraductal NeoplasmsPancreatic NeoplasmsTranscriptomeAgedFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMaleMiddle AgedNeoplasm GradingBiomarkers, Tumor

Identifiers

PMID39969959
PMCPMC12045729

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.